Novartis Quarterly Profit Drops as Diovan, OTC Sales Slump

Novartis AG’s first-quarter profit dropped 8 percent on generic competition and manufacturing glitches at a consumer-health products factory in Nebraska.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.